Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine
Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine
复制标题
DOI：
10.1016/s0166-6851(03)00077-x
复制
发表时间：
2003-05-01
影响因子：
1.5
通讯作者：
Lyon, JA
中科院分区：
文献类型：
--
作者：
Angov, E;Aufiero, BM;Lyon, JA
裂殖子表面蛋白-1（42）（MSP-1（42））是针对红细胞疟疾寄生虫的主要候选疫苗。我们在大肠杆菌中克隆并表达了恶性疟原虫MSP-1（42）（3D 7克隆）。通过使用镍-、Q-和羧甲基（CM）-取代的树脂将抗原纯化至大于95%的均一性。最终产品，命名为恶性疟原虫裂殖子蛋白-1（FMP 1），其内毒素水平显著低于FDA标准。基于结合构象依赖性mAb，其结构正确，并且稳定。来自用弗氏佐剂中的FMP 1接种的兔的功能性抗体在体外抑制寄生虫生长，并且还抑制MSP-1的二次加工（42）。用GlaxoSmithKline Biologicals（GSK）佐剂、AS 02 A或明矾配制的FMP 1在恒河猴（Macaca mulatta）中是安全的和免疫原性的。出版社：Elsevier Science B. V.
Merozoite Surface Protein-1(42) (MSP-1(42)) is a leading vaccine candidate against erythrocytic malaria parasites. We cloned and expressed Plasmodium falciparum MSP-1(42) (3D7 clone) in Escherichia coli. The antigen was purified to greater than 95% homogeneity by using nickel-, Q- and carboxy-methyl (CM)-substituted resins. The final product, designated Falciparum Merozoite Protein-1 (FMP1), had endotoxin levels significantly lower than FDA standards. It was structurally correct based on binding conformation-dependent mAbs, and was stable. Functional antibodies from rabbits vaccinated with FMP1 in Freund's adjuvant inhibited parasite growth in vitro and also inhibited secondary processing Of MSP-1(42). FMP1 formulated with GlaxoSmithKline Biologicals (GSK) adjuvant, AS02A or alum was safe and immunogenic in rhesus (Macaca mulatta) monkeys. Published by Elsevier Science B.V.